ReviewMolecular therapy. Nucleic acids2025
Innovative aptamer approaches in glial tumor diagnostics and therapy: Progress and future directions.
Review in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glial tumors, particularly glioblastomas, remain among the most challenging cancers to diagnose and treat due to their heterogeneity, infiltrative nature, and the protective blood-brain barrier that impedes drug delivery. Aptamers-short, single-stranded nucleic acids selected for high-affinity target binding-have emerged as promising agents in neuro-oncology, offering advantages such as high specificity, low immunogenicity, and superior tissue penetration compared to conventional antibodies. This review outlines recent advancements in aptamer-based technologies for the diagnosis and treatment of glial brain tumors. We describe the use of aptamers in molecular imaging, liquid biopsy platforms, intraoperative tumor visualization, and the targeted delivery of therapeutic agents, including small molecules, small interfering RNAs (siRNAs), and immunomodulators. The integration of aptamer systems with nanotechnology and AI is accelerating the development of sensitive, non-invasive diagnostic tools and multifunctional theranostic platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.